Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...

Every four minutes, someone in the U.S. is diagnosed with blood cancer, and thousands of patients with blood cancers like ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Provider prioritization of relationship-building alongside explanations could foster trust and facilitate open information exchange, supporting informed decisions,” researchers wrote.

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Very sick patients who get a bone marrow transplant at Medical University of South Carolina survive at a much higher rate ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.